EmCyte Corporation
EmCyte Corporation is a privately held regenerative medicine company founded in 1999 that designs and manufactures FDA-cleared PURE SupraPhysiologic concentrating systems for point-of-care autologous biologic preparation (PRP, BMC, adipose tissue), selling hardware and disposable kits directly to licensed healthcare professionals.
- Company typePrivate
- Founded1999
- HeadquartersFort Myers, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What EmCyte Corporation does
EmCyte Corporation is a privately held regenerative medicine company founded in 1999 by Patrick Pennie and headquartered in Fort Myers, Florida. The company designs and manufactures point-of-care autologous biologic preparation systems, with its core platform being the PURE® SupraPhysiologic Concentrating Systems suite. The product portfolio spans centrifuge hardware (Sapphire Centrifuge), disposable concentrating kits (PurePRP SP, PureBMC SP, Progenikine, AspiraDome, ASPIRE, CORE Ultrafiltration System), and an AI-assisted platelet analyzer (RegeniSTAT). Six FDA 510(k) clearances and eight granted U.S. patents anchor the company's regulatory and IP position.
The company sells directly to licensed healthcare professionals — primarily sports medicine physicians, orthopedic specialists, and regenerative medicine practitioners — through a registration-gated e-commerce portal (emcyte.com/emcyte.net) that requires credential verification. The revenue model is a hardware-plus-consumables razor/blade construct: capital equipment drives acquisition, while single-use disposable kits generate recurring revenue. Distribution is domestic only (United States), with no disclosed international sales infrastructure.
Demand generation and customer lock-in are reinforced by an integrated training ecosystem: Gulf Coast Biologics (a nonprofit training center founded 2019), the BioEdge Musculoskeletal Training Program (live-patient training across West and East Coast clinical faculty), and Biofyl Scientific Research (an affiliated regenerative science laboratory). The company also operates a clinical research collaboration program supporting IRB-approved physician-led studies, which doubles as both a customer-acquisition channel and an evidence-generation function.
EmCyte Corporation firmographics
Firmographics- Name
- EmCyte Corporation
- Legal name
- EmCyte Corporation
- Website
- https://emcyte.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EmCyte Corporation is a privately held regenerative medicine company founded in 1999 that designs and manufactures FDA-cleared PURE SupraPhysiologic concentrating systems for point-of-care autologous biologic preparation (PRP, BMC, adipose tissue), selling hardware and disposable kits directly to licensed healthcare professionals.
- Ownership category
- akta.pro rank
EmCyte Corporation industry classification
Industry- Product category
- Regenerative Medicine Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors) (HLAAAJAC)
Keywords
Where EmCyte Corporation is headquartered
LocationHeadquarters
- HQ city
- Fort Myers
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
EmCyte Corporation business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- Hardware Sales (Centrifuge Systems): Sale of Sapphire Centrifuge machines and other processing equipment to healthcare facilities for point-of-care biologic preparation
- Disposable Concentrating Kits: Single-use kits for PRP, BMC, and adipose tissue processing including PurePRP SP, PureBMC SP, Progenikine, and AspiraDome systems
- Professional Training Services: Hands-on in-clinic training programs for physicians and clinicians covering ultrasound-guided injections, biologic formulation, and treatment protocols through BioEdge Musculoskeletal Training
- Clinical Research Support: Services including regulatory guidance, IRB-approved clinical trial design, biologic product provisioning, and data collection/analysis support for physician-led research
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Standard pricing through registration |
Go-to-market motion4 records
Distribution channels3 records
Marketing channels6 records
EmCyte Corporation product offering
Product offeringCore offering
EmCyte Corporation designs, manufactures and sells the PURE® SupraPhysiologic Concentrating System platform for point-of-care preparation of autologous biologics, including platelet-rich plasma (PRP), bone marrow concentrate (BMC) and adipose tissue concentrate. The product portfolio comprises single-use concentrating kits (PurePRP SP, PureBMC SP, Progenikine), reusable processing instruments (Sapphire Centrifuge, ASPIRE bone marrow harvest kits), the AI-assisted RegeniSTAT platelet analyzer, and the CORE ultrafiltration system, sold directly to licensed healthcare professionals and complemented by paid clinical training programs.
Product overview
EmCyte Corporation offers a comprehensive portfolio of regenerative biologic preparation systems centered on the PURE® SupraPhysiologic Concentrating System platform. The product line includes: AspiraDome (guided buffycoat collection technology), PurePRP SP (platelet-rich plasma concentrating system), PureBMC SP (bone marrow concentrating system), CORE Ultrafiltration System (plasma protein concentration), Progenikine (adipose tissue concentrating system), ASPIRE Bone Marrow Harvesting Systems, RegeniSTAT Platelet Analyzer (AI-assisted analysis), and Sapphire Centrifuge (processing equipment). These products work together to enable point-of-care preparation of autologous biologics including PRP, bone marrow concentrate, and adipose concentrate for regenerative medicine applications.
Differentiator
Problem solved
Functional benefit
Brands
- PURE SupraPhysiologic: Proprietary concentrating system technology delivering supraphysiologic concentrations of platelets and biologics for point-of-care applications.
- AspiraDome
- PurePRP SP
- PureBMC SP
- CORE
- Progenikine
- ASPIRE
- RegeniSTAT
- Sapphire Centrifuge
- BioEdge
Products and services
- PURE® SupraPhysiologic Concentrating System Suite of proprietary concentrating technologies empowering physicians to prepare highly potent, customizable autologous biologics at the point of care, with a patient-first, closed-system design supporting PRP, BMC and adipose tissue preparations. Sold to licensed healthcare professionals and medical institutions.
- AspiraDome Patented guided buffycoat collection device within the PURE SupraPhysiologic system that optimizes platelet and progenitor cell collection, delivering over 80% platelet yield in leukocyte-poor PRP and over 85% yield in monocyte/neutrophil-rich PRP with less than 1% RBC content. Sold to licensed healthcare professionals preparing autologous PRP.
- PurePRP SP (PurePRP® SupraPhysiologic) Proprietary platelet concentrating system that delivers the highest concentrations of deliverable platelets at the point of care in under 10 minutes using a double-spin technique, allowing physicians to customize PRP formulations (neutrophil-rich/poor) and control final treatment volume. Sold to licensed healthcare professionals performing PRP therapy.
- PureBMC SP (PureBMC® SupraPhysiologic) Bone marrow concentrating system engineered to deliver superior BMC formulations enriched with hematopoietic stem cells, mesenchymal stem cells, deliverable platelets and cytokine mediators at the point of care, using double-spin technology with preparation time under 10 minutes. Sold to licensed healthcare professionals performing bone marrow concentrate therapy.
- CORE™ Ultrafiltration System Low-volume 20 kDa plasma ultrafiltration system using polysulfone filtration material that selectively retains key plasma biomolecules (albumin, fibrinogen, growth factors) while removing excess fluid and small waste molecules, enhancing bioactivity in PRP and other autologous biologics. Sold to licensed healthcare professionals.
- Progenikine® Adipose Concentrating System Adipose concentrating system that compresses adipocytes and eliminates tumescent solution and oil contamination to yield a purified adipose concentrate using dynamic aspiration technology, processing in under five minutes in a fully closed system. Sold to licensed healthcare professionals in plastic and reconstructive surgery and related specialties.
- ASPIRE™ Bone Marrow Harvesting System Advanced clinically sophisticated bone marrow harvesting system featuring side fenestrated architecture with a 180-degree sequestering pattern for minimally invasive, high-purity collection of bone marrow aspirate with preserved cell viability. Sold to licensed healthcare professionals performing bone marrow procedures.
- RegeniSTAT™ Platelet Analyzer First-of-its-kind platelet analyzer providing full performance analysis comparing baseline platelet values to final PRP biologic, using AI-assisted Viscoelastic Focusing technology to deliver lab-grade analysis from a single drop of blood in under five minutes. Sold to licensed healthcare professionals and clinics requiring point-of-care biologic validation.
- Sapphire Centrifuge Centrifuge machine designed to streamline regenerative biologics processing, handling EmCyte PRP, BMC and Adipose concentrating systems in a single unit with pre-programmed optimized settings, intuitive touchscreen interface and a 31-pound footprint. Sold to licensed healthcare professionals and clinics as the processing instrument for EmCyte concentrating kits.
- BioEdge Musculoskeletal Training Program Paid in-clinic, live-patient hands-on training program covering ultrasound-guided injections, biologic formulation and treatment protocols, taught by expert clinical board faculty on the West Coast (Dr. Rowan Paul) and East Coast (Dr. Moises Irizarry-Román). Sold to licensed healthcare professionals seeking procedural mastery in regenerative biologic therapies.
Quantifiable outcome
- ≥80% platelet yield in leukocyte-poor PRP; ≥85% yield in monocyte/neutrophil-rich PRP
- +5 more outcomes
Companies that use EmCyte Corporation
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
EmCyte Corporation technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature8 records
EmCyte Corporation partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Gulf Coast BiologicscoreNonprofit educational and training center dedicated to the advancement of regenerative medicine through physician education and hands-on training. Provides clinical publications library and webinar programs supporting EmCyte biologic products. Serves as key GTM channel for training and education.
- Biofyl Scientific ResearchcoreIndependent state-of-the-art regenerative science laboratory dedicated to pioneering breakthroughs in cellular regeneration. Equipped with cutting-edge technology and advanced analytical platforms for fundamental regenerative cell component research and medical applications.
Scale indicators4 records
Recent moves9 records
Expansion highlights12 records
EmCyte Corporation competitors and assessment
Company assessmentDirect peers
- Arthrex: Arthrex is a leading orthopedic medical device company with a prominent autologous PRP concentrating system (Angel System) and an extensive orthopedic sports medicine portfolio. Directly competes with EmCyte for physician-of-the-practice accounts performing PRP/BMC procedures in orthopedics and sports medicine.
- Terumo BCT (Harvest Technologies): Terumo BCT acquired Harvest Technologies and sells SmartPrep and other point-of-care platelet concentration systems to hospitals and cell-therapy labs. Directly overlaps with EmCyte's PurePRP and PureBMC product lines in autologous biologic preparation for regenerative medicine.
- Isto Biologics: Isto Biologics develops autologous bone marrow concentrate and orthobiologic products (e.g., the Magellan system) used in spine and orthopedic surgery. Directly competes with EmCyte's PureBMC and ASPIRE bone marrow harvesting devices in orthobiologics.
- Royal Biologics: Royal Biologics is a pure-play orthobiologics company selling PRP, fibrin, and autologous cell-processing kits to orthopedic and sports medicine physicians. Directly comparable to EmCyte's disposable concentrating kit franchise and competes head-to-head on kit economics.
- Celling Biosciences: Celling Biosciences (now CorGenix) sells point-of-care autologous cell-processing systems and PRP kits for orthopedic and spine surgeons. Closely comparable to EmCyte's PurePRP/PureBMC franchise in delivery model, customer base, and clinical use cases.
Broad incumbents
- Exactech (now part of TPG/Novo Holdings): Exactech is a broad orthopedic implant and biologics incumbent with a regenerative-medicine portfolio addressing orthopedic surgeons. Overlaps with EmCyte's sports medicine and orthopedic use cases but operates as a wide-portfolio incumbent rather than a concentrating-systems specialist.
- Stryker: Stryker is a diversified medical device incumbent with a sports medicine and biologics business serving orthopedic surgeons. Provides competitive pressure on EmCyte through hospital contracts and bundled orthopedic solutions but does not specialize in point-of-care concentrating systems.
- DePuy Synthes (Johnson & Johnson): DePuy Synthes is Johnson & Johnson's orthopedic and regenerative medicine arm, offering a wide range of sports medicine implants and orthobiologics. Indirectly competes with EmCyte via surgeon relationships and bundled biologic offerings rather than point-of-care concentrating devices.
- Zimmer Biomet: Zimmer Biomet is a global orthopedic incumbent with sports medicine and biologic solutions. Competes for orthopedic surgeon accounts but as a portfolio incumbent rather than a focused autologous concentrating-systems company.
Emerging players
- Elutia (formerly Aziyo Biologics): Elutia is an emerging orthobiologics company developing regenerative solutions for soft tissue and bone repair. Partial overlap with EmCyte's regenerative biologics franchise; smaller scale and earlier-stage but addresses adjacent clinical use cases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
EmCyte Corporation social profiles
Digital presenceEmCyte Corporation compliance and trust
Trust signalCompliance2 records
EmCyte Corporation financial estimates
Financial estimateRevenue estimate
Valuation estimate
EmCyte Corporation leadership team
Management profileNumber of profiles
Profiles15 records
EmCyte Corporation subsidiaries and ownership
Company hierarchySubsidiaries2 records
EmCyte Corporation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EmCyte Corporation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EmCyte Corporation
What does EmCyte Corporation do?
EmCyte Corporation designs, manufactures and sells the PURE® SupraPhysiologic Concentrating System platform for point-of-care preparation of autologous biologics, including platelet-rich plasma (PRP), bone marrow concentrate (BMC) and adipose tissue concentrate. The product portfolio comprises single-use concentrating kits (PurePRP SP, PureBMC SP, Progenikine), reusable processing instruments (Sapphire Centrifuge, ASPIRE bone marrow harvest kits), the AI-assisted RegeniSTAT platelet analyzer, and the CORE ultrafiltration system, sold directly to licensed healthcare professionals and complemented by paid clinical training programs.
Is EmCyte Corporation a public or private company?
EmCyte Corporation is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was EmCyte Corporation founded?
EmCyte Corporation was founded in 1999. It employs 11 to 50 people.
Where is EmCyte Corporation based?
EmCyte Corporation is headquartered in Fort Myers, United States, in the North America region.
How does EmCyte Corporation make money?
Four revenue lines are on record. Hardware Sales (Centrifuge Systems) is the primary driver. The others are disposable Concentrating Kits, professional Training Services and clinical Research Support.
Who are EmCyte Corporation's main competitors?
Direct peers on record are Arthrex, Terumo BCT (Harvest Technologies), Isto Biologics, Royal Biologics and Celling Biosciences. Broad incumbents are Exactech (now part of TPG/Novo Holdings), Stryker, DePuy Synthes (Johnson & Johnson) and Zimmer Biomet. Elutia (formerly Aziyo Biologics) is listed as an emerging player.
Does EmCyte Corporation have an API?
No public API is recorded for EmCyte Corporation.
What industry is EmCyte Corporation in?
EmCyte Corporation's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAAAJAC, Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors). Its NAICS code is 334510 and its SIC code is 3841.